Ieq Capital LLC Cuts Stake in Boston Scientific Corporation $BSX

Key Points

• Ieq Capital LLC reduced its holdings in Boston Scientific Corporation by 11.5%, selling 8,149 shares and now owns 62,732 shares valued at approximately $6.3 million.
• Boston Scientific reported its quarterly earnings showing $5.06 billion in revenue and an EPS of $0.75, outperforming analysts' expectations.
• Multiple brokerages have maintained a positive outlook on Boston Scientific, with a consensus rating of "Buy" and average target price of $117.50.

Ieq Capital LLC lessened its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,732 shares of the medical equipment provider's stock after selling 8,149 shares during the quarter. Ieq Capital LLC's holdings in Boston Scientific were worth $6,328,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BSX. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG raised its holdings in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE boosted its position in Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares in the last quarter. Comerica Bank grew its holdings in Boston Scientific by 1.5% in the fourth quarter. Comerica Bank now owns 276,689 shares of the medical equipment provider's stock valued at $24,714,000 after purchasing an additional 4,074 shares during the last quarter. Finally, Rehmann Capital Advisory Group increased its position in shares of Boston Scientific by 6.9% in the fourth quarter. Rehmann Capital Advisory Group now owns 5,245 shares of the medical equipment provider's stock valued at $468,000 after buying an additional 339 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 180,586 shares of company stock valued at $18,925,509. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.2%

NYSE BSX traded down $0.19 during mid-day trading on Monday, reaching $105.56. 4,066,860 shares of the stock were exchanged, compared to its average volume of 5,853,664. The stock has a market capitalization of $156.41 billion, a PE ratio of 62.83, a PEG ratio of 2.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1-year low of $79.53 and a 1-year high of $108.94. The business's fifty day simple moving average is $104.53 and its 200 day simple moving average is $102.12.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent research reports. Robert W. Baird boosted their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Truist Financial raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Oppenheimer upped their target price on Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company increased their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.